Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO

Stock News

Aug 13

The Hong Kong Stock Exchange disclosed on August 12 that Suzhou Zelgen Biopharmaceuticals Co., Ltd. (ticker: 688266.SH) has submitted a listing application to the main board, with CICC serving as the sole sponsor. The company previously filed for a Hong Kong IPO on December 19, 2025.

According to the prospectus, Suzhou Zelgen Biopharmaceuticals is a comprehensive biopharmaceutical enterprise focused on the discovery, development, and commercialization of innovative small molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematology. As of the latest practicable date, the company has four marketed drugs: Zepson (Donafenib Tosylate Tablets), the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; Zepel (Gecacitinib Hydrochloride Tablets), the first innovative JAK inhibitor developed in China for treating myelofibrosis; Zepning (Recombinant Human Thrombin), the only recombinant human thrombin in China developed using recombinant DNA technology and successfully commercialized; and Zesuning (Recombinant Human Thyrotropin Beta for Injection), the only recombinant human thyrotropin approved in China for diagnostic use in postoperative follow-up of differentiated thyroid cancer patients, utilized for radioactive iodine whole-body imaging and serum thyroglobulin monitoring.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1166586489"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1166586489\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1166586489?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 06:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166586489","market":"other","top_or_hot":-1,"title":"Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO","media":"Stock News","content":"<p>The Hong Kong Stock Exchange disclosed on August 12 that <b>Suzhou Zelgen Biopharmaceuticals Co., Ltd.</b> (ticker: 688266.SH) has submitted a listing application to the main board, with CICC serving as the sole sponsor. The company previously filed for a Hong Kong IPO on December 19, 2025.<br><br>According to the prospectus, <b>Suzhou Zelgen Biopharmaceuticals</b> is a comprehensive biopharmaceutical enterprise focused on the discovery, development, and commercialization of innovative small molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematology. As of the latest practicable date, the company has four marketed drugs: <b>Zepson</b> (Donafenib Tosylate Tablets), the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; <b>Zepel</b> (Gecacitinib Hydrochloride Tablets), the first innovative JAK inhibitor developed in China for treating myelofibrosis; <b>Zepning</b> (Recombinant Human Thrombin), the only recombinant human thrombin in China developed using recombinant DNA technology and successfully commercialized; and <b>Zesuning</b> (Recombinant Human Thyrotropin Beta for Injection), the only recombinant human thyrotropin approved in China for diagnostic use in postoperative follow-up of differentiated thyroid cancer patients, utilized for radioactive iodine whole-body imaging and serum thyroglobulin monitoring.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nListing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-13 06:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The Hong Kong Stock Exchange disclosed on August 12 that <b>Suzhou Zelgen Biopharmaceuticals Co., Ltd.</b> (ticker: 688266.SH) has submitted a listing application to the main board, with CICC serving as the sole sponsor. The company previously filed for a Hong Kong IPO on December 19, 2025.<br><br>According to the prospectus, <b>Suzhou Zelgen Biopharmaceuticals</b> is a comprehensive biopharmaceutical enterprise focused on the discovery, development, and commercialization of innovative small molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematology. As of the latest practicable date, the company has four marketed drugs: <b>Zepson</b> (Donafenib Tosylate Tablets), the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; <b>Zepel</b> (Gecacitinib Hydrochloride Tablets), the first innovative JAK inhibitor developed in China for treating myelofibrosis; <b>Zepning</b> (Recombinant Human Thrombin), the only recombinant human thrombin in China developed using recombinant DNA technology and successfully commercialized; and <b>Zesuning</b> (Recombinant Human Thyrotropin Beta for Injection), the only recombinant human thyrotropin approved in China for diagnostic use in postoperative follow-up of differentiated thyroid cancer patients, utilized for radioactive iodine whole-body imaging and serum thyroglobulin monitoring.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1166586489","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166586489","pubTimestamp":1786574109,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The Hong Kong Stock Exchange disclosed on August 12 that Suzhou Zelgen Biopharmaceuticals Co., Ltd. (ticker: 688266.SH) has submitted a listing application to the main board, with CICC serving as the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688266":"泽璟制药-U","BK1574":"生物医药B类股","BK1191":"制药","01477":"欧康维视生物-B","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF"},"translate_title":"上市更新：苏州泽尔根生物制药再次申请香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":1,"01477":1,"IPOS":1,"HEXmain":1},"content_text":"The Hong Kong Stock Exchange disclosed on August 12 that Suzhou Zelgen Biopharmaceuticals Co., Ltd. (ticker: 688266.SH) has submitted a listing application to the main board, with CICC serving as the sole sponsor. The company previously filed for a Hong Kong IPO on December 19, 2025.According to the prospectus, Suzhou Zelgen Biopharmaceuticals is a comprehensive biopharmaceutical enterprise focused on the discovery, development, and commercialization of innovative small molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematology. As of the latest practicable date, the company has four marketed drugs: Zepson (Donafenib Tosylate Tablets), the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China; Zepel (Gecacitinib Hydrochloride Tablets), the first innovative JAK inhibitor developed in China for treating myelofibrosis; Zepning (Recombinant Human Thrombin), the only recombinant human thrombin in China developed using recombinant DNA technology and successfully commercialized; and Zesuning (Recombinant Human Thyrotropin Beta for Injection), the only recombinant human thyrotropin approved in China for diagnostic use in postoperative follow-up of differentiated thyroid cancer patients, utilized for radioactive iodine whole-body imaging and serum thyroglobulin monitoring.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}